Randomized clinical trials are considered the gold standard for assessing the safety and efficacy of new drugs and vaccines. Over the past decade many low- and middle-income countries (LMICs) have received significant investments in a bid to develop capacity to conduct vaccine trials. Even so, some LMICs still struggle to build sustainable capabilities or provide qualified regulatory oversight for conducting vaccine trials.
The aim of this course is to offer a specialized and tailor-made training to prepare and build sites with international standards for clinical development.
All international and national guidelines with regards to GCP, ICH and local regulatory and ethical rules are considered during this training.